title: [Epidermal growth factor receptor expression and epidermal growth factor blood plasma content in simple and complex endometrial hyperplasia].
abstract: The goal of our study was to concurrently determine the prognostic significance of Epidermal Growth Factor Receptor (EGFR) expression in endometrium and Epidermal Growth Factor (EGF) blood content in simple and complex hyperplasia. In order to detect EGFR expression, immunohistochemical examination of endometrial scarp from 35 patients was done along with HPLC (High performance liquid chromatography) method, for measuring EGF blood plasma content. The numerical data obtained were processed statistically using computer program SPSS-12. According to the results: 1. A significant/marked increase in EGF blood plasma level together with pronounced EGFR expression in simple endometrial hyperplasia (without atypia) suggests that simple hyperplasia is likely to transform into complex form, while unchanged level of EGF against the background of mild EGFR expression is probably indicative of not very bad prognosis. 2. Normal indices of EGF blood plasma level in simple endometrial hyperplasia (without atypia), accompanied by mild EGFR expression is suggestive of good prognosis. 3. A sharp or extremely sharp increase in EGF blood plasma level with pronounced EGFR expression in complex endometrial hyperplasia (without atypia) is likely to indicate poor prognosis that may lead to the transformation into atypical form. However, unchanged EGF blood plasma level against the background of mild EGFR expression in complex endometrial hyperplasia (without atypia) is likely to point to not very bad prognosis. 4. A marked increase in EGF blood plasma level with a pronounced EGFR expression in complex endometrial hyperplasia (without atypia) is likely to indicate poor prognosis that may lead to the transformation into atypical form. Because it is evident that drastic increase in EGF blood plasma level is not necessary, other factor should be suspected to play the major role, i.e the substance that will (or will not) withstand neoplasia.
authors: David Tvildiani Medical University, Department of Human Morphology and Pathology, Tbilisi, Georgia.
authors: N
authors: N
authors: Dznelashvili
authors: David Tvildiani Medical University, Department of Human Morphology and Pathology, Tbilisi, Georgia.
authors: D
authors: D
authors: Kasradze
authors: David Tvildiani Medical University, Department of Human Morphology and Pathology, Tbilisi, Georgia.
authors: A
authors: A
authors: Tavartkiladze
authors: David Tvildiani Medical University, Department of Human Morphology and Pathology, Tbilisi, Georgia.
authors: A
authors: A
authors: Mariamidze
mesh_terms: D004714:Endometrial Hyperplasia / Q000378:metabolism* / Q000473:pathology*; D004815:Epidermal Growth Factor / Q000097:blood*; D066246:ErbB Receptors / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D011379:Prognosis
chemical_list: D004815:Epidermal Growth Factor; C512478:EGFR protein, human; D066246:ErbB Receptors